SYHA1813

SYHA1813 is an orally available, potent multikinase inhibitor that selectively targets vascular endothelial growth factor receptors (VEGFRs) and colony-stimulating factor 1 receptor (CSF1R). It is designed to inhibit angiogenesis and macrophage-mediated tumor progression by blocking VEGFR and CSF1R signaling pathways. Preclinical studies have demonstrated that SYHA1813 efficiently crosses the blood–brain barrier and exhibits significant antitumor activity against glioblastoma (GBM), including temozolomide-insensitive tumors. The drug has also shown efficacy in meningioma models by inducing cell cycle arrest, apoptosis, cellular senescence, activating the P53 pathway, and impairing DNA damage repair via the ATM/CHK/P53 signaling pathway. Early clinical trials indicate manageable toxicity profiles with encouraging antitumor responses in patients with recurrent high-grade gliomas or advanced solid tumors[1][2][5][6].